Market Movers (8-K)
NASDAQ
Kailera Therapeutics reported strong Q2 2026 progress, advancing its ribupatide injection and oral programs, with cash runway extending into mid-2028.
Insider Trading (Form 4)
NASDAQ
Nur Nicholson, Chief Technology Officer of Kailera Therapeutics, Inc., received 220,000 shares of common stock on September 7, 2026.
NASDAQ
Kathleen Tregoning, Chief Corporate Affairs Officer at Kailera Therapeutics, Inc., has exercised stock options for 175,000 shares of common stock.
Schedule 13G - Passive Investments
NASDAQ
CPP Investment Board and its subsidiary, CPP Investment Board Private Holdings (4) Inc., have reported beneficial ownership of 7,304,688 shares, representing 5.6% of Kailera Therapeutics, Inc.'s common stock.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.3% of Kailera Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has reported a beneficial ownership of 8.9% in Kailera Therapeutics, Inc., acquiring 11,511,853 shares.